 SUNNYVALE, Calif., Sept. 14, 2021 PRNewswire -- Accuray Incorporated NASDAQ: ARAY announced today that data from the PACE Prostate Advances in Comparative Evidence trial indicate the companys CyberKnife robotic radiotherapy platform is superior to conventional linear accelerators in reducing the incidence of late grade two or higher bladder toxicity associated with prostate cancer stereotactic body radiation therapy SBRT treatments. 